Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Patent
1995-01-13
1997-01-14
Jordan, Kimberly
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
514323, 514321, 514417, 514418, 514825, A61K 31535, A61K 31445, A61K 3140
Patent
active
055939902
ABSTRACT:
The present invention comprises a group of compounds that effectively inhibit angiogenesis. More specifically, thalidomide and various related compounds such as thalidomide precursors, analogs, metabolites and hydrolysis products have been shown to inhibit angiogenesis and to treat disease states resulting from angiogenesis. Importantly, these compounds can be administered orally.
REFERENCES:
patent: 2830991 (1958-04-01), Keller et al.
patent: 3560495 (1971-02-01), Frankus et al.
patent: 3563986 (1971-02-01), Frankus et al.
patent: 3625946 (1971-12-01), Koch et al.
patent: 3705162 (1972-12-01), Graudums et al.
patent: 4552888 (1985-11-01), Koppel et al.
patent: 4994443 (1991-02-01), Folkman et al.
patent: 5001116 (1991-03-01), Folkman et al.
patent: 5021404 (1991-06-01), Folkman et al.
patent: 5134127 (1992-07-01), Stella et al.
patent: 5443824 (1995-08-01), Piacquadio
Medline: 84121350, Belaube et al. (1983).
Taylor, et. al., Nature, 297: p. 307 (1982).
Folkman, et. al., Science, 221: p. 719 (1983).
Sidkey, et. al., Cancer Res., 47: pp. 5155-5161 (1987).
White, et. al., New England J. Med., 320: pp. 1197-1200 (1989).
Helm, Arzneimittleforschung, 31 (i/6): 941-949 (1981).
Blaschke, Arneimittleforschung, 29: pp. 1640-1642 (1972).
Shealy et. al., Chem. Indus., p. 1030 (1965).
Eger, K. et al., Synthesis, Central Nervous System Activity and Teratogenicity of a Homothalidomide, Arzneim.-Forsch/Drug Res. 40 (II). Nr. 10(1990), pp. 1073-1075.
Fabro, S. et al., Teratogenic Activity of Thalidomide and Related Compounds, Life Sciences, vol. 3, pp. 987-992, 1964.
Eriksson, Sven O., Synthesis and Alkaline Hydrolysis of some N-substituted Phthalimides, Acta Pharm. Sucecica 10, pp. 63-74 (1973).
Fickentscher, K., Sterochemical Properties and Teratogenic Activity of some Tetrahydrophthalimides, Mol. Pharmacology 13, pp. 133-141. (1977).
Jonsson, N. Ake, et al. Chemical Structure and Teratogenic Properties, Acta Pharm. Succica 9, pp. 521-542 (1972).
Matsuyama, Toshifumi, Cytokines and HIV infection: is AIDS a Tumor Necrosis Factor Disease?, AIDS 1991, vol. 5 No. 12, pp. 1405-1417.
Jonsson, N. Ake, et al. Chemical Structure and Teratogenic Properties, Acta Pharm. Succica 9, pp. 431-446 (1972).
Hendler, Sheldon S. et al., Thalidomide for Autoimmune Disease, Medical Hypotheses 10:pp. 437-443 (1983).
Jonsson, N. Ake, et al. Chemical Structure and Teratogenic Properties, Acta Pharm. Succica 9, pp. 543-562 (1972).
Weidner, Noel, et. al., Tumor Angiogenesis Correlates with Metastasis in Invasive Prostate Carcinoma, American J. of Pathology, vol. 143, No. 2, pp. 401-409 (Aug. 1993).
Srivastava, Anurag, et al., The Prognostic Signifiance of Tumor Vasculairty in Intermediate-Thickness (.076-4.0 mm Thick) Skin Melanoma, American J. of Pathology, vol. 133, No. 2, pp. 419-423 (Nov. 1988).
Folkman, Judah, et al., Induction of Angiogenesis during the transition from hyperplasia to neoplasia, Nature, vol. 339, pp. 58-61 (May 4, 1989).
Gimbrone, Jr., Michael A., et. al., Tumor Dormancy in Vivo by Prevention of Neovascularization, J. of Experimental Medicine, vol. 136, pp. 261-276 (1972).
Gimbrone, Jr., Michael A., et. al., Tumor Growth and Neovascularization: An Experimental Model Using the Rabbit Cornea, J. of the National Cancer Institute, vol. 52, No. 2, pp. 413-427 (Feb. 1974).
Knighton, D., Avascular and Vascular Phases of Tumour Growth in the Chick Embryo, Br. J. Cancer, 35, 347, pp. 347-356 (1977).
D'Amato, Robert J., et. al., Thalidomide is a inhibitor of angiogenesis, Proc. Natl. Acad. Acad. Sci. USA, vol. 91, pp. 4082-4085, (Apr. 1994).
Chen, Tian-Ling, et. al., Plasma Pharmacokinetics and Urinary Excretion of Thalidomide after Oral Dosing in Heathy Male Volunteers, Drug Metabolism and Disposition, vol. 17, No. 4, pp. 402-405 (1989).
Vogelsang, Georgia B., et. al., Thalidomide for the Treatment of Chronic Graft-Versus-Host Disease, New England J. of Medicine, 326: pp. 1055-1058, (Apr. 16), 1992.
Brem, et. al., J. Neurosurg., 74: pp. 441-446 (1991).
Crum, et. al., Science, 230: 1375 et. seq. (1985).
Khan, J. S., Wilson, M. C., Taylor, T. V., "Treatment of ulcerative colitis with thalidomide," British Medical Journal, 24 Mar. 1979, p. 792.
Belaube, P., Garcin, G., Marchand, J. P., Privat, Yl, "Should Thalidomide be Rehabilitated?," Sem. Hop. Paris, vol. 59, No. 45, pp. 3101-3104, Dec. 8, 1983. Memoranda.
Jordan Kimberly
The Children's Medical Center Corporation
LandOfFree
Methods and compositions for inhibition of angiogenesis does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions for inhibition of angiogenesis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for inhibition of angiogenesis will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1388335